Skip to main content

Appraisals in progress

Patients, carers and patient organisations - please see our New medicines needing your views page for answers to some questions you might have about making a submission.

Clinical experts - please see our Clinical expert opinion for medicine appraisals page for background information.

We'd like to receive your submission before the stated deadline (so we can prepare the meeting papers). But we'll still try to include any that arrive late.

Medicine name: buprenorphine / naloxone (Suboxone®)

Reference number: 4590

Indication: Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Suboxone is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 15/02/2021

AWMSG meeting date: 20/04/2021

Medicine name: perampanel (Fycompa®)

Reference number: 4770

Indication: Adjunctive treatment of partial-onset seizures (POS) with or without secondarily generalised seizures in patients from 4 to < 12 years of age.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 12/03/2021

AWMSG meeting date: 19/05/2021

Medicine name: indacaterol / glycopyrronium / mometasone (Enerzair Breezhaler®)

Reference number: 3141

Indication: Maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long‑acting beta2‑agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 26/03/2021

AWMSG meeting date: 19/05/2021

Medicine name: conestat alfa (Ruconest®)

Reference number: 4519

Indication: Treatment of acute angioedema attacks in children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 04/12/2020

AWMSG meeting date: 19/05/2021

Medicine name: dolutegravir (Tivicay®)

Reference number: 4611

Indication: In combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 28/04/2021

AWMSG meeting date: 14/07/2021

Medicine name: everolimus (Votubia®)

Reference number: 2142

Indication: Adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex (TSC).

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 28/06/2021

AWMSG meeting date: 14/09/2021